Alemtuzumab: management of complications
Evidence-based neurology checklist on alemtuzumab: management of complications: ITP: monitoring Full blood count: monthly Patient symptom questionnaire: monthly Monitor until 48 months after last Alemtuzumab infusion ITP: indications for haematology referral ITP: treatment options Autoimmune…
ITP: monitoring
- Full blood count: monthly
- Patient symptom questionnaire: monthly
- Monitor until 48 months after last Alemtuzumab infusion
ITP: indications for haematology referral
ITP: treatment options
Autoimmune nephropathy
Autoimmune hypothyroidism
Autoimmune hyperthyroidism
Rituximab
Acronym: ITP
References
- Cuker A, Bass AD, Nadj C, et al. Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management. Mult Scler 2019; 20:1352458518816612 (Epub ahead of print).
- Devonshire V, Phillips R, Wass H, Da Roza G, Senior P. Monitoring and management of autoimmunity in multiple sclerosis patients treated with alemtuzumab: practical recommendations. J Neurol 2018; 265:2494-2505.
- Alroughani R, Altintas A, Al Jumah M, et al. Pregnancy and the use of disease-modifying therapies in patients with multiple sclerosis: benefits versus risks. Mult Scler Int 2016; 2016:1034912.
- Meltzer E, Campbell S, Ehrenfeld B, et al. Mitigating alemtuzumab-associated autoimmunity in MS: A "whack-a-mole" B-cell depletion strategy. Neurol Neuroimmunol Neuroinflamm 2020; 7:e868.
